
Hemophilia A Prophylaxis Treatments Compared
5 FDA-approved drugs, plus 1 in development, side by side from the current prescribing labels. Newest label Jun 2026. Checked October 17, 2026.
The full Hemophilia A guide, with open trials and help paying →
Five drugs on this page are FDA-approved to prevent bleeds in hemophilia A.
- Altuviiio is factor VIII itself, infused into a vein once a week, and the same product treats bleeds and covers surgery.
- The other 4 are non-factor drugs given under the skin at home. Hemlibra, approved in 2017, is injected weekly, every 2 weeks or every 4 weeks. Hympavzi is once a week, Alhemo once a day, and Qfitlia can be as few as 6 injections a year.
- Alhemo, Hympavzi and Qfitlia are also approved for hemophilia B.
- In their trials, treated bleeds per year fell by 71-97% compared with on-demand treatment or no prophylaxis, and people on weekly Altuviiio averaged 0.7 treated bleeds a year.
- Qfitlia carries a boxed warning for blood clots and gallbladder disease and requires blood tests to set the dose.
- A sixth drug, denecimig, is under FDA review after its Phase 3 trial. On October 2, 2026 Novo Nordisk said the review was extended over manufacturing-site fixes, with no new decision date.
Latest for hemophilia A
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Label changeThe FDA approved a label update for HympavziFDA
Free email alert
Email me the day the FDA decides on Denecimig
You get one email when the decision is public, plus new trials and FDA news for this condition.
You'll get trial alerts and disease updates for Hemophilia A, and you can turn either off anytime. We never share your email. Privacy policy
5 approved hemophilia A treatments at a glance
How each drug is given, how often, who it is approved for and when it was first approved, from the current FDA label.
A year on each hemophilia A treatment
Every dose in a year, drawn to the label schedule, so you can see at a glance how often each one is given.
Counts follow the label schedule for a full year on the maintenance dose. Drugs given in cycles or adjusted to blood tests have no fixed count, so their schedule is written out instead.
What the pivotal hemophilia A trials showed
The primary result from the trial each FDA approval rests on, as reported on the label.
Hemophilia A treatment side effects and warnings
Hemlibra and Qfitlia carry a boxed warning, the FDA's strongest. The rest list their main precautions. Side effect rates show how many people in each drug's trials reported each one, whether or not the drug caused it.
Hemophilia A treatments in Phase 3 or under FDA review
Investigational drugs with a Phase 3 trial, shown separately because their results are not from a label. Status as of the date in each row.
Help paying for hemophilia A treatment
Drugmaker copay and free-drug programs, plus charity funds for the condition, checked every week.
One email when the FDA acts on a Hemophilia A treatment, a label changes or a new trial opens. Never a newsletter.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Hemophilia A treatment questions people ask
Altuviiio vs Hemlibra: which is better?
No trial has compared them. Altuviiio is factor VIII, infused into a vein once a week; Hemlibra copies factor VIII's job and is injected under the skin weekly, every 2 weeks or every 4 weeks. People on weekly Altuviiio averaged 0.7 treated bleeds a year in XTEND-1, and people without inhibitors on weekly Hemlibra averaged 1.5 in HAVEN 3, but the trials differ, so this is not a head-to-head result. Hemlibra is approved for people with factor VIII inhibitors; Altuviiio was studied only in people without them. Altuviiio also treats bleeds and covers surgery, while Hemlibra only prevents bleeds.
What is the least frequent hemophilia A prophylaxis?
Qfitlia (fitusiran), which starts at 50mg under the skin once every 2 months and is adjusted by antithrombin blood levels to as few as 6 injections a year. Hemlibra can be given every 4 weeks, Hympavzi is weekly and Alhemo is daily.
Is Hemlibra better than Hympavzi?
No trial has compared them. In HAVEN 3, people without inhibitors on Hemlibra had 1.5 treated bleeds a year on weekly dosing against 38.2 with no prophylaxis. In BASIS, people on Hympavzi had 3.2 treated bleeds a year against 39.9 during their earlier on-demand period. The designs differ, so the numbers are not a head-to-head result. Both are weekly or less often, self-injected, and need no routine drug-level monitoring.
Which hemophilia A drugs work with inhibitors?
All 4 approved non-factor drugs cover people with factor VIII inhibitors on their current labels: Hemlibra since its first approval, Alhemo for inhibitors first, and Hympavzi and Qfitlia under their current labels. Alhemo is approved from age 12, Hympavzi from age 6 under its June 2026 label, Hemlibra for all ages and Qfitlia from age 12.
Is denecimig approved for hemophilia A?
No. Novo Nordisk filed it with the FDA in September 2025 after the FRONTIER2 trial, where monthly denecimig cut treated bleeds by about 99% against on-demand treatment and 43% against prior factor prophylaxis. Novo had expected a decision in the third quarter of 2026, but on October 2, 2026 it said the FDA had extended the review over manufacturing-facility fixes, with no new timeline and no problems found in the clinical data. Novo aims for a US launch in the first half of 2027 if approved. It received a positive opinion from the EU's medicines committee in September 2026 under the name Frehemgo.
What happened to Roctavian?
Roctavian, the one-time gene therapy for severe hemophilia A approved in June 2023, was withdrawn from the market by BioMarin in February 2026. It is listed on this page for the record but is no longer available.
More on Hemophilia A at Trial Friend
Where every number on this page comes from
Approved-drug facts are from the current FDA prescribing information on DailyMed or the FDA's own site, with the label's effective date. Investigational-drug facts are from ClinicalTrials.gov and the sources named in each row.
- Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl (efanesoctocog alfa)) prescribing information, Sanofi (Bioverativ), label dated Dec 2025. DailyMed. Pivotal trial: ClinicalTrials.gov
- Alhemo (concizumab-mtci) prescribing information, Novo Nordisk, label dated Jul 2025. DailyMed. Pivotal trial: ClinicalTrials.gov
- Hympavzi (marstacimab-hncq) prescribing information, Pfizer, label dated Jun 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
- Hemlibra (emicizumab-kxwh) prescribing information, Genentech (Roche), label dated Jul 2025. DailyMed. Pivotal trial: ClinicalTrials.gov
- Qfitlia (fitusiran) prescribing information, Sanofi (Genzyme); discovered by Alnylam, label dated Sep 2025. DailyMed. Pivotal trial: ClinicalTrials.gov
- denecimig (Mim8); EU brand name Frehemgo, Novo Nordisk: ClinicalTrials.gov record; Novo Nordisk press release, April 29, 2026. Checked October 4, 2026.
This page compares what the FDA labels and pivotal trials report. It is not medical advice, and no trial on this page compared these drugs with each other. Written and checked by Jason Hunter; the method is on the editorial standards page.